Previous Close | 74.86 |
Open | 74.39 |
Bid | 74.59 x 1000 |
Ask | 74.60 x 800 |
Day's Range | 74.33 - 75.51 |
52 Week Range | 53.22 - 80.59 |
Volume | |
Avg. Volume | 11,916,808 |
Market Cap | 159.077B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 24.75 |
EPS (TTM) | 3.01 |
Earnings Date | Oct 26, 2022 |
Forward Dividend & Yield | 2.16 (2.88%) |
Ex-Dividend Date | Jun 30, 2022 |
1y Target Est | 81.38 |
Subscribe to Yahoo Finance Plus to view Fair Value for BMY
There's no better time than to build a strong watchlist during a serious market correction. This story covers five NYSE stocks to watch and consider buying. In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.
Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.
Bristol Myers Squibb Co (NYSE: BMY) and 2seventy bio Inc (NASDAQ: TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma. The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen. The interim analysis demonstrated a statistically significant improvement in progression-free survival. Related Content: